US 12,440,471 B2
Compositions and methods for the treatment of bronchopulmonary dysplasia (BPD) and BPD-associated pulmonary hypertension
Suchismita Acharya, Grapevine, TX (US); and Pragnya Das, Secane, PA (US)
Assigned to AyuVis Research, Inc., Fort Worth, TX (US)
Filed by AyuVis Research, Inc., Fort Worth, TX (US)
Filed on Jul. 26, 2022, as Appl. No. 17/873,453.
Claims priority of provisional application 63/227,819, filed on Jul. 30, 2021.
Prior Publication US 2023/0097886 A1, Mar. 30, 2023
Int. Cl. A61K 31/351 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61P 29/00 (2006.01)
CPC A61K 31/351 (2013.01) [A61K 9/0078 (2013.01); A61K 45/06 (2013.01); A61P 29/00 (2018.01)] 39 Claims
 
1. A method for preventing at least one of: neonatal lung injury, bronchopulmonary dysplasia (BPD), or BPD-associated pulmonary hypertension (BPD-PH), comprising:
administering to the subject in need thereof a therapeutically effective amount of a lung surfactant isolated from a lung extract or a synthetic equivalent thereof; and
a compound of formula (I) or stereoisomer, enantiomer, tautomer or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein X═O; Y=Phenyl, a phenyl group substituted with at least one methyl, a phenyl group substituted with at least one nitro, a phenyl group substituted with at least one nitrogen containing group, a phenyl group substituted with at least one boron containing group; Z=none; R═H, C(O)R2, SO2R2; R1═H, C(O)R2, SO2R2; R2=ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, NH2, NR3R4; R3, R4=ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, three to six membered cycloalkyl, wherein an amount of the compound is selected to prevent the at least one of: neonatal lung injury, bronchopulmonary dysplasia (BPD), or BPD-associated pulmonary hypertension (BPD-PH), wherein the compound of formula (I) is provided in an amount of about 0.5 to 100 mg/kg that is synergistic with the lung surfactant.